(Q81627605)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

1

Vernon K Sondak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Lawrence E Flaherty

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

9633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

89-90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961011-9

7 January 2021

10.1016/S0140-6736(08)61011-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18620932%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference